Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin in Type 2 Diabetes Patients on High-Dose U-500 Insulin
NCT02597309Phase 4Withdrawn
- Sponsor
- Joslin Diabetes Center
- Start
- Nov 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of canagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Joslin Diabetes Center. Planned start Nov 2015; status: withdrawn.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02597309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597309.